Microarray analysis is used to detect small copy number changes (deletions and duplications) that may be associated with genetic syndromes and phenotypic abnormalities. However, there are limitations to what microarrays are able to detect. We present a patient referred for microarray in whom chromosome analysis identified a more complex structural rearrangement than was indicated by the microarray. Our studies included Affymetrix Cytoscan HD array, chromosome analysis and fluorescence in situ hybridization (FISH) using a subtelomere probe targeting chromosome 3. Array analysis revealed a 6.45-Mb terminal duplication of 3q28q29 and a 1.02-Mb terminal deletion of 12p13.33. This suggested an unbalanced translocation derivative. In order to investigate visibility of the rearrangement, chromosome analysis was performed, revealing an additional balanced complex chromosome rearrangement involving chromosomes 3 and 11, including a translocation with breakpoints at 3p13 and 11p11.2, as well as a paracentric inversion of segment 3p25p13 translocated onto chromosome 11. Subtelomere FISH confirmed that the duplicated chromosome 3q material observed in the array analysis was localized to distal 12p. This case clearly illustrates the combined utilization of classic cytogenetics, FISH and array technologies to better characterize chromosomal abnormalities.

Keywords:
Complex rearrangement, Microarray, Structural chromosome abnormality
1.
Angle B, Yen F, Hersh JH, Gowans G: Patient with terminal duplication 3q and terminal deletion 5q: comparison with the 3q duplication syndrome and distal 5q deletion syndrome. Am J Med Genet A 116A:376-380 (2003).
2.
Ballif BC, Theisen A, Coppinger J, Gowans GC, Hersh JH, et al: Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal microduplication. Mol Cytogenet 1:8 (2008).
3.
Bi W, Borgan C, Pursley AN, Hixson P, Shaw CA, et al: Comparison of chromosome analysis and chromosomal microarray analysis: what is the value of chromosome analysis in today's genomic array era? Genet Med 15:450-457 (2013).
4.
Chen CP, Chang YL, Chern SR, Wu PS, Su JW, et al: Prenatal diagnosis of partial trisomy 3q (3q27.3→qter) and partial monosomy 14q (14q31.3→qter) of paternal origin associated with fetal hypotonia, arthrogryposis, scoliosis and hyperextensible joints. Gene 516:132-137 (2013).
5.
Delaloy C, Elvira-Matelot E, Clemessy M, Zhou XO, Imbert-Teboul M, et al: Deletion of WNK1 first intron results in misregulation of both isoforms in renal and extrarenal tissues. Hypertension 52:1149-1154 (2008).
6.
Grossmann V, Müller D, Müller W, Fresser F, Erdel M, et al: ‘Essentially' pure trisomy 3q27→qter: further delineation of the partial trisomy 3q phenotype. Am J Med Genet A 149A:2522-2526 (2009).
7.
ISCN (2013): An International System for Human Cytogenetic Nomenclature, Shaffer LG, McGowan-Jordan J, Schmid M (eds); (S. Karger, Basel 2013).
8.
Lisi EC, Hamosh A, Doheny KF, Squibb E, Jackson B, et al: 3q29 interstitial microduplication: a new syndrome in a three-generation family. Am J Med Genet A 146A:601-609 (2008).
9.
Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, et al: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 86:749-764 (2010).
10.
Su PH, Chen JY, Chen SJ, Hung HM: Partial duplication of 3q and distal deletion of 10q inherited from a maternal balanced translocation. J Formos Med Assoc 103:853-857 (2004).
11.
Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, et al: Human hypertension caused by mutations in WNK kinases. Science 293:1107-1112 (2001).
12.
Yatsenko SA, Mendoza-Londono R, Belmont JW, Shaffer LG: Omphalocele in trisomy 3q: further delineation of phenotype. Clin Genet 64:404-413 (2003).
13.
Zafra de la Rosa G, Venegas-Vega CA, Monroy N, Contreras-Bucio G, Friedrich U, et al: Trisomy 3q25.1-qter and monosomy 8p23.1-pter in a patient: cytogenetic and molecular analysis with delineation of the phenotype. Am J Med Genet A 136:259-264 (2005).
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.